The Australian has published its fourth annual edition of The List – Top 100 Innovators 2024: The Next Wave. Identifying the ...

Wave Life Sciences (WVE) shares rallied 74.1% in the last trading session to close at $14.90. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Fintel reports that on October 16, 2024, Raymond James upgraded their outlook for Wave Life Sciences (NasdaqGM:WVE) from ...

This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The ...

Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential treatment for a genetic disorder that causes lung and liver diseases. Its stock surged as ...

While RNA-medicine developer Wave Life Sciences Ltd. brought in a clinical data win, it also got knocked back a step as a major collaborator will go its separate way. That didn’t stop Wave’s stock ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...

Wave Life Sciences is a clinical-stage biotechnology company based in Cambridge, MA, dedicated to unlocking the potential of RNA medicines to transform human health. With a robust pipeline focused on ...

Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of ...